Why it was recalled
CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Product description
Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, 100 tablets per bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120, NDC: 29033-056-01
Lot numbers, UPCs & expiration codes
MET200501 07/2022
Where it was sold
Nationwide
What to do if you have this product
- Compare the lot number and expiration date on your package with the codes above.
- Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
- If you have symptoms you think are related, contact your doctor. In an emergency call 911.
- Report side effects to FDA MedWatch at 1-800-FDA-1088.
Recall details
- Recall number
- D-0227-2021
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- Jan 4, 2021
- FDA report date
- Jan 20, 2021
- Quantity
- 6958 Bottles
- Recall type
- Voluntary: Firm initiated
- Recalling firm
- Nostrum Laboratories Inc
Original FDA data
Every field from FDA enforcement report D-0227-2021, exactly as published.
Show all FDA fields
- City
- Kansas City
- State
- MO
- Status
- Ongoing
- Country
- United States
- Event ID
- 87080
- Address
- 1800 N Topping Ave
- Code information
- MET200501 07/2022
- Postal code
- 64120-1228
- Report date
- Jan 20, 2021
- Product type
- Drugs
- Recall number
- D-0227-2021
- Classification
- Class II
- Recalling firm
- Nostrum Laboratories Inc
- Product quantity
- 6958 Bottles
- Reason for recall
- CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
- Voluntary / mandated
- Voluntary: Firm initiated
- Product description
- Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, 100 tablets per bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120, NDC: 29033-056-01
- Distribution pattern
- Nationwide
- Recall initiation date
- Jan 4, 2021
- Initial firm notification
- Press Release
- Center classification date
- Jan 14, 2021